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Melanoma is the most lethal form of skin cancer. New technologies have resulted in major advances in the
diagnosis and treatment of melanoma and other cancer types. Recently, some studies have investigated
the role of circular RNAs (circRNAs) in different cancers. CircRNAs are a member of long noncoding RNA
family mainly formed through back-splicing and have a closed loop structure. These molecules affect
several biological and oncogenic cascades in diverse ways via acing as microRNA sponge, interacting with
RNA-binding proteins and acting as a transcription regulator. In this review, we made an insight into the
impact of circRNA dysregulation in the melanoma tumorigenesis based on the presented evidences.
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Melanoma, the cancerous growth of melanocytes, is the most aggressive form of all skin cancers [1]. This cancer
is more common in the men, with worse survival rate than women [2,3]. Recently, its incidence, morbidity and
mortality are increasing worldwide. The American Cancer Society estimated that in 2019 melanoma was the fourth
most common cancer in men and the fifth most common cancer in women [4]. There are multiple distinct categories
of melanocytic neoplasms which are different in cell of origin, role of ultraviolet radiation, clinical and histological
indications, mutation pattern, predisposing germ line alterations and sites of metastasis [5]. Based on the primary
site of neoplasm and morphologic aspects of the early growth phase, melanoma divided into four main types:
superficial spreading melanoma (50–75%), nodular melanoma (15–35%), lentigo malignant melanoma (5–15%)
and acrallentiginous melanoma (5–10%) [6,7].
Recent investigations and new technologies have resulted in major advances in the diagnosis and treatment of this
cancer. In addition to conventional therapies for melanoma such as surgical intervention and radiation therapy, other
treatment options including chemotherapy, immunotherapy, genetically targeted therapy and nanotechnology have
been used [8–10]. Although melanoma is treatable in its early stages, it is still a therapeutic challenge and advanced
malignant melanoma carries a poor prognosis. Patients with stages II and III have a 10-year survival rate of 77
and 69%, respectively [11]. One of the main problems in the treatment of melanoma is low response rate to the
present treatment modalities due to inherent resistance of melanoma cells to chemotherapeutic agents [12]. Melanoma
arises from a complex interaction between environmental and genetic factors. A well-established risk factor for
melanoma development is exposure to ultraviolet radiation, which induces cellular stress signaling, DNA damage
and disrupts DNA repair systems [13,14]. Multiple pathogenic mutations in melanoma affect genes involved in key
signaling pathways that control proliferation (mitogen-activated protein kinase [MAPK], NF1, NRAS, and BRAF)
Biomark. Med. (Epub ahead of print) ISSN 1752-036310.2217/bmm-2019-0567 C© 2020 Future Medicine Ltd
